Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels.
Jérôme RobertEmily B ButtonBrian YuenMegan GilmourKevin KangArvin BahrabadiSophie StukasWenchen ZhaoIva KulicCheryl L WellingtonPublished in: eLife (2017)
Amyloid plaques, consisting of deposited beta-amyloid (Aβ), are a neuropathological hallmark of Alzheimer's Disease (AD). Cerebral vessels play a major role in AD, as Aβ is cleared from the brain by pathways involving the cerebrovasculature, most AD patients have cerebrovascular amyloid (cerebral amyloid angiopathy (CAA), and cardiovascular risk factors increase dementia risk. Here we present a notable advance in vascular tissue engineering by generating the first functional 3-dimensioinal model of CAA in bioengineered human vessels. We show that lipoproteins including brain (apoE) and circulating (high-density lipoprotein, HDL) synergize to facilitate Aβ transport across bioengineered human cerebral vessels. These lipoproteins facilitate Aβ42 transport more efficiently than Aβ40, consistent with Aβ40 being the primary species that accumulates in CAA. Moreover, apoE4 is less effective than apoE2 in promoting Aβ transport, also consistent with the well-established role of apoE4 in Aβ deposition in AD.
Keyphrases
- high density
- cognitive decline
- endothelial cells
- cardiovascular risk factors
- high fat diet
- induced pluripotent stem cells
- mild cognitive impairment
- end stage renal disease
- subarachnoid hemorrhage
- cerebral ischemia
- tissue engineering
- pluripotent stem cells
- newly diagnosed
- chronic kidney disease
- ejection fraction
- cardiovascular disease
- type diabetes
- multiple sclerosis
- resting state
- brain injury
- insulin resistance
- functional connectivity
- low density lipoprotein